The tolerability of nab-paclitaxel and gemcitabine has opened the door to a host of novel combination strategies that use the two agents as a backbone.
Pancreatic Cancer
With the wealth of data demonstrating efficacy in the metastatic setting, researchers are now assessing nab-paclitaxel/gemcitabine as both an adjuvant and neoadjuvant treatment for patients with pancreatic cancer.
First-line therapies with improved efficacy might encourage use of second-line treatment in a larger proportion of patients with advanced pancreatic cancer.
A multitude of factors contribute to the selection of frontline treatment for patients with advanced pancreatic cancer, specifically in regard to selecting first- and second-line therapies.
Given the benefits of nab-paclitaxel plus gemcitabine and FOLFIRINOX, efforts have been made to improve the toxicity profiles through dose modifications.
Frontline therapies for patients with metastatic pancreatic cancer have advanced in the past 5 years, with the FDA approval of nab-paclitaxel plus gemcitabine.
Evolving Paradigms in Pancreatic Cancer: References
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
